Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Amgen, Inc. : Amgen : FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
04/27/2012 | 01:22pm CEST

Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones.

According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem.

"We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development.

Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million.

A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful.

Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months.

Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN
09/21 PDL BIOPHARMA : Appoints Dominique Monnet as President
09/21 AMGEN (AMGN) ALERT : Johnson Fistel Announces Investigation of Amgen Inc.; Inves..
09/20 AMGEN : deCODE Study Reveals an Ancient Achilles Heel in the Human Genome
09/20 CYTOKINETICS : Announces Dosing of First Patient in Japan in GALACTIC-HF, Phase ..
09/19 AMGEN : New FOURIER analysis Shows Repatha Reduces Cardiovascular Events In Pati..
09/19 AMGEN : and Allergans anti-cancer biosimilar Mvasi receives FDA approval
09/19 AMGEN : US FDA approves Amgen and Allergan`s Avastin biosimilar
09/16 AMGEN : A Biosimilar Cure for Sky-High Cancer Drug Prices
09/16 AMGEN : Gains FDA Approval for Avastin Biosimilar
09/15 NOVARTIS : Sandoz says Humira biosimilar clears clinical hurdle
More news
News from SeekingAlpha
09/21 Esperion Therapeutics Remains Undervalued
09/21 FDA's Woodcock says clinical trials system "broken"
09/19 Biotech And Pharma Stocks To Soak Up At The Bottom
09/19 AMGEN AND ALLERGAN : Avastin Biosimilar Approval Part 2
09/18 THE IM-CAPITAL STRENGTH 20-STOCK UNI : Update September 2017
Financials ($)
Sales 2017 22 841 M
EBIT 2017 11 797 M
Net income 2017 8 120 M
Finance 2017 5 838 M
Yield 2017 2,43%
P/E ratio 2017 16,86
P/E ratio 2018 16,59
EV / Sales 2017 5,71x
EV / Sales 2018 5,51x
Capitalization 136 B
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 187 $
Spread / Average Target 0,33%
EPS Revisions
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN28.70%136 186
GILEAD SCIENCES15.40%107 896
ACTELION21.20%29 716